Dacomitinib/Dacomitinib specifications

Dacomitinib is available with FDA-approved diagnostic tests (e.g., therascreen EGFR RGQ First-line treatment of metastatic non-small cell lung cancer (NSCLC) in patients with tumor positive for EGFR exon 19 deletion (DELL9) or exon 21 (L858R) substitution mutation detected by PCR kit, Cobas EGFR Mutation Test v2). Dacomitinib is one of several commonly recommended treatments for previously untreated patients with non-small cell lung cancer who have EGFR activating mutations. The FDA designates an orphan drug for this condition.

The specifications of dacomitinib mainly refer to the dosage of a single tablet and the number of tablets contained in each box or bottle. Common specifications of dacomitinib are 15 mg per tablet, 30 mg per tablet, and 45 mg per tablet. Each box contains 30 tablets. Such a specification design not only takes into account the patient's medication needs, but also facilitates the storage and portability of medications. Each strength of dacomitinib has its specific applicable population and dosage regimen. Doctors will choose appropriate specifications and dosages based on the patient's specific condition, physical condition, and treatment goals. Therefore, when purchasing and using dacomitinib, patients must follow their doctor’s recommendations and guidance to ensure the safety and effectiveness of the medication.

At the same time, there may also be certain differences in price between different specifications of dacomitinib. The price of a box of 15mg*30 tablets of the original drug sold domestically may be more than RMB 1,000; the price of a box of 45mg*30 tablets of the original drug sold overseas may be more than RMB 20,000; and the price of a box of generic drugs in Laos of 45mg*30 tablets may be around RMB 800 (prices may fluctuate due to exchange rates). When purchasing drugs, patients should choose appropriate specifications and purchasing channels based on their financial status and medication needs.